Vascular Protection Module 3: Metabolic Syndrome

Faculty

Needs Statement

Many therapies currently exist today for the treatment of hypertension, however, there still remains a critical need to better establish and define the concept of vascular protection. To appreciate this concept, it is important to understand the data which results in a reduction in the risk of cardiovascular outcomes (MI, stroke or death) associated with some treatment regimens. This educational program will educated the audience on the cardiovascular benefits associated with vascular protection rather than simply treating patients to control hypertension.

Target Audience

This program is designed to educate Primary Care Physicians, Endocrinologists, Nephrologists and Cardiologists on the management of cardiovascular disease progression and the long term benefits associated with optimal treatment plans.

Objectives

1. List the interrelated metabolic risk factors that to lead to increased risk of atherosclerotic cardiovascular disease (ASCVD);
2. Describe currently available evidence for treatment of metabolic syndrome (MBS);
3. Given a patient case, design monitoring plan for the safety and efficacy of treatment for metabolic risk factors

Accreditation

Medicine
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Kentucky College of Medicine and CTI Clinical Trial & Consulting Services. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Each physician should claim only those hours of credit actually spent in the educational activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

Faculty Disclosure

Dr Solomon receives contract research support and consultation fees from Novartis Pharmaceuticals.
Dr Vardeny has no relevant financial relationships to disclose.

Activity Sponsorship

This activity is jointly sponsored by the University of Kentucky and CTI Clinical Trial & Consulting Services. Supported by an unrestricted educational grant from King Pharmaceuticals.